-
Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study
SGLT2 inhibitor use was not associated with an increased risk of severe UTI compared to use of DPP-4 inhibitors among patients with type 2 diabetes.
Q18-09Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis
Apixaban is associated with lower risks of ischemic stroke and major bleeding, compared with rivaroxaban, and similar risks of these outcomes when compared with dabigatran. Rivaroxaban is associated with an increased risk of major bleeding and a similar risk of ischemic stroke, when compared with dabigatran.
Q16-13AOff-label postpartum use of domperidone in Canada: a multidatabase cohort study
The incidence of cardiac death and ventricular tachyarrhythmia is very low in postpartum women. Although this potential increased risk is low and could not be confirmed in this large study, it should be discussed when considering treatment options for individual patients.
Q16-10Methadone containing products used for opioid use disorder
Methadone is used for the treatment of opioid use disorder and in 2014/2015, most Canadian public drug plans transitioned from a compounded formulation to a more stable pre-mixed formulation. Subsequently, there has been reports that some patients may experience decreased effectiveness with the newer methadone formulation. This project was deemed not feasible.
Q20-20Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study
There was no clear evidence that rheumatoid arthritis on bDMARDs were less likely to discontinue or switch bDMARDs if they received concomitant csDMARD therapy.
Q14-01Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study
Direct oral anticoagulants (DOACs) and warfarin provide similar effectiveness for ischemic stroke prevention for patients with NVAF in Canada. However, DOACs carry a lower risk of major bleeding and all-cause mortality compared with warfarin.